Ascendis Pharma A/S: stock overview

ASNDNASDAQHealthcare · Pharmaceutical Preparations

Price

$271.19

November 17, 2026Market cap $16.4B

What Ploutos Investor adds for Ascendis Pharma A/S

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 11 fiscal years, from 2015
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

In short

Ascendis Pharma A/S had revenue of $845M in the fiscal year to December 31, 2025 and a net loss of $268M. Revenue grew by 153.0% a year on average over the last 5 years. It holds more cash than debt, by $488M. It pays no dividend.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 17, 2026.

Its SEC filings
Market cap
$16.4B
60.61M shares
P/E
–
Revenue, fiscal year
$845M
+153.0% a year over 5 years
Net margin
-31.7%

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

+64.3% a year over 2 years

  • 202520-F
    Revenue$845M
  • 202420-F
    Revenue$376M
  • 202320-F
    Revenue$295M

Fiscal years in figures

ASND's revenue, profit, cash flow and dividend with each year-end price, from 2015 to 2022, 8 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $8.0B
$16.4B
Enterprise value 
$15.9B
P/E 
–
EV / EBIT 
–
EV / Revenue 
18.9
P/B 
–
FCF yield 
–
Earnings yield 3-year median: -4.9%
–

Profitability

Gross margin 
86.8%
Operating margin 
-18.9%
Net margin 3-year median: -104.0%
-31.7%
ROIC 
-16.5%
ROIC, 5-year average 
-44.9%
ROE 
–

Growth

Revenue, yearly change 
+98.0%
EPS, yearly change 
–
FCF, yearly change 
–
Revenue, average a year 
+153.0%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$1.6B
Total debt 
$1.1B
Net cash 
$488M
Net debt / EBITDA 
–
Interest cover 
–
Current ratio 
–

Balance sheet of December 31, 2025.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
0.12%
Total returned 
0.12%
Shares, yearly change 
+4.7%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
Ascendis Pharma A/S
Exchange
NASDAQ
Industry (SIC)
2834 · Pharmaceutical Preparations
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
EUR
Shares
60.61M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Ascendis Pharma A/S's filings show?

These are Ascendis Pharma A/S's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about ASND

Didn't find what you were looking for?

Ask us
What is ASND's market cap?

Ascendis Pharma A/S's market cap is $16.4B, at a price of $271.19 on November 17, 2026 and 60.61M shares.

How much revenue does ASND have?

Ascendis Pharma A/S had revenue of $845M in the fiscal year to December 31, 2025. Over the last 5 years it changed by +153.0% a year on average.

Does ASND pay a dividend?

No. Ascendis Pharma A/S paid no regular dividend over the last 12 months.

Where do the figures come from?

From Ascendis Pharma A/S's SEC filings (its annual report on 20-F) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.